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 Technologically mediated health care raises problems of quality of information, cross border
 practice, and patient confidentiality. Nicolas Terry probes the legal aspects of these complexities, and
 Benedict Stanberry adds a European perspective
 Identifying the regulatory agenda for health infor
 mation is not difficult. The quality of publicly available
 health information, cross border medical and phar
 macy practice, and the privacy of medical records
 appear on the radar screens of most public health and
 consumer protection organisations. Left unregulated,
 any of these issues can cause considerable harm. Each
 issue also embodies difficult tensions: state versus
 federal rights, increased access to care versus quality
 assurance, and confidentiality versus professional
 discourse.
 US state and federal legal systems have not
 achieved a coherent approach to regulating the
 dissemination of health information. Furthermore, the
 American experience will not always transfer directly
 to publicly funded medicine and government initia
 tives. Nevertheless the American experience with
 private sector ehealth is an instructive model, even if
 some areas have been neglected and others over
 regulated.
 Regulating the quality of online health
 information
 Concerns about widespread inaccuracies in online
 health information are speculative and intuitive rather
 than based on robust research. Berland's quality assess
 ments, at least for English language sites and well edu
 cated users, suggest the picture is not so gloomy as
 critics expected.1
 Public law regulation of health information may
 conflict with US guarantees of free speech, and
 differences of opinion among medical professionals
 make the broad regulation of health advice difficult
 Consequendy, intervention through public law is
 reserved for obviously dangerous health content where
 government agencies can apply traditional consumer
 protection, drug regulation, and fraud powers,, as with
 the Federal Trade Commission's "Operation Cure.All."2
 Arguments about freedom of speech can be used
 to defend private legal actions against web sites
 Summary points
 Quality of publicly available health information,
 cross border medical and pharmacy practice, and
 privacy of records will be key issues for European
 regulators
 Concerns about medical advice sites may be
 exaggerated
 US regulators have yet to find the appropriate
 balance between risk and benefits of cross border
 practice
 New US federal laws on health privacy appear
 cumbersome but may be instructive for other
 legal systems
 offering medical advice, and precedents from actions
 against publishers of "advice" or "how to" books show
 that such claims are hard to win.3 Case by case,
 retrospective, private law "regulation" may, however, be
 judicially more acceptable than blanket public law
 regulation.
 Since regulation can do only so much to deter the
 web's snake oil salesmen, the focus inevitably shifts to
 strengthening the role of the market by reducing the
 costs of health information to the consumer.
 "Kitemark" or "trustmark" schemes seek to limit the
 need for consumers to assess the quality of
 information themselves by encouraging providers to
 rate their own contributions or to comply with codes of
 conduct With compliance or rating in place, a technol
 ogy layer can be added that leverages downstream
 filtering technology or upstream filtering through
 membership in a distinct top-level domain4;
 Medcertain is an example of downstream filtering
 technology,5 whereas the World Health Organization
 Center for Health
 Law Studies, Saint
 Louis University
 School of Law, 3700
 Lindell Blvd, St
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 favours the upstream approach.6 Filtering persuades
 content producers to participate in ratings systems
 because search engines and, increasingly, browsers
 may be set to ignore unrated sites.
 One approach that is emerging in the United
 States is to combine the evaluation of online content?
 for example, kitemarking?with private accreditation, a
 quality assurance system widely adopted by bricks and
 mortar healthcare providers.7 For this, a provider of
 online health information would subscribe to an
 accrediting agency's quality standards and pay the
 agency to check for compliance. Accreditation is a par
 ticularly interesting model because it uses a well
 respected method of quality assurance that is already
 recognised in private malpractice actions and brings
 traditional healthcare bodies and online providers
 under the same quality assessment umbrella. The use
 of such a model will also be of interest to litigators as
 US courts have held that failure to comply with appli
 cable accreditation standards may constitute sufficient
 evidence of medical malpractice.
 Whether simple or sophisticated, and whether rely
 ing on self regulation or rating by third parties,
 kitemarking systems are not without their difficulties,8
 critics,9 or legal pitfalls, including the potential liability
 of rating organisations to private legal actions.10 The
 voluntary adoption of codes of conduct in good faith
 by health websites should not be trivialised or discour
 aged. Equally, the potential for fraudulent self rating
 and the likelihood that kitemarking will reduce
 consumers' natural skepticism about health infor
 mation continue to trouble US regulators; this may
 explain a lack of enthusiasm relative to that of their
 colleagues in Europe.
 Controlling cross border practice
 With the appearance of online medical advice sites, it is
 easy to overlook the proportion of cross border health
 information provided by physicians and pharmacists.
 In the United States, healthcare institutions are subject
 to national accreditation standards, and they educate
 their medical students according to a national curricu
 lum with a view toward national testing. Medical
 professionals, however, are exclusively regulated by
 state authorities. Most state licensing and disciplinary
 systems assume that there will be some level of cross
 border medical practice by providers who consult with
 colleagues in other states or treat their travelling
 patients; these activities are not required to be licensed.
 Such exceptions aside, however, US states insist on
 local licensing.
 Theoretically, increasing cross border services
 through technologically mediated health care should
 stimulate interest in an overall liberalisation of cross
 border practice. In reality, state authorities are
 strengthening their legislation to deter interstate
 ehealth services that either originate from or are
 received within their borders.11 While some of the
 voices raised against ehealth may have protectionist
 accents, the reality is that states' disciplinary and quality
 assurance powers are tied to the licensing process and
 there is no political will for moving such functions to a
 federal body.
 In the United States federal regulators have legal









 Nevertheless, pharmacists, like doctors, face a state-by
 state system of licensure and discipline. Licensing and
 quality issues, however, are not such a problem in
 pharmacy because it is easier for pharmacy chains to
 comply with multiple licensing requirements. The
 National Association of Boards of Pharmacy has facili
 tated compliance and consumer education by setting
 up a national system for trustmarking online pharma
 cies.12 Additional state by state regulation of pharma
 cists may, however, be imminent At least one state now
 believes it can achieve indirectly what it has failed to do
 directly: stopping internet doctors from writing
 prescriptions for its citizens by placing the responsibil
 ity on the pharmacist to make sure that the
 prescription was the product of a traditional doctor
 patient interaction.13 Such regulations will function as
 an indirect but effective method of controlling cross
 border medical practice.
 This stringent regulation of ehealth exchanges
 across borders assumes too readily that indirect health
 care is inferior. Valid questions have been raised about
 the quality of email communications between doctor
 and patient,14 particularly doctors' responses to
 unsolicited email from patients. Though they pose
 some marginally interesting legal questions, these are
 essentially transitional issues that call for better educa
 tion of doctors more than for regulatory intervention.
 A more important issue is whether doctors must
 disclose the risks of remote consultations. The Ameri
 can Medical Informatics Association has cogently
 argued that an informed consent instrument should
 "provide instructions for when and how to escalate the
 contact from being via the internet to phone calls and
 office visits" and that it should "describe the security
 mechanisms that are in place."15 Some US states
 already require specific consent for remote, technologi
 cally mediated care and professional organisations
 increasingly are recommending the use of encrypted
 systems for doctor-patient communications.16 Such
 regulation is appropriate when motivated by concerns
 over quality or patient autonomy but less so if designed
 to discourage non-traditional care.
 It may be time to review the marketing activities of
 pharmaceutical companies both on the internet and in
 more traditional media. Direct to the consumer adver
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 using is commonplace in the United States. The
 Federal Drug Agency's Center for Drug Evaluation and
 Research seeks valiandy to enforce advertising
 standards17 through its general regulatory standards
 and processes.18 In comparison with the constant
 barrage of pharmaceutical advertising aimed at US
 consumers, however, regulatory efforts tend to pale
 into insignificance. Against the background of the
 tightly controlled environment of doctors and patients
 under managed care, pharmaceutical companies are
 using direct to consumer advertising to try and
 persuade patients to pay for items not covered by their
 managed care plans, while simultaneously using both
 patients and doctors to coerce managers of health
 plans to add the company's products to their formular
 ies. The importance to pharmaceutical manufacturers
 of direct advertising to consumers, however, may be
 illustrated by manufacturers' sanguine acceptance of
 increased exposure to liability for their products when
 they circumvent the traditional channel?doctor to
 patient?for drug information.19
 Apart from suggesting the need for increased
 direct regulation (such as the American Medical
 Assoociation's demand that direct to consumer adver
 tising should contain warnings that a doctor might
 actually recommend a different treatment20), the
 growth of direct advertising presents difficult issues of
 ethical and possibly legal conflicts of interest for health
 advice sites that seek click-stream revenue from their
 links to the sites of pharmaceutical manufacturers or
 pharmacies.21
 Privacy of medical information
 Health websites on both sides of the Atlantic have
 failed to establish acceptable standards of data protec
 tion.22 Somewhat ironically, the European Union's
 green paper exploring the development of a
 community-wide approach to consumer protection
 was published within days of the Federal Trade
 Commission's announcement that it was abandoning
 plans to introduce any new online privacy legislation.23
 Without such legislation, the commission's ability to
 protect consumer privacy on the internet is limited to
 cases where websites breach their own published
 privacy policies.24 Websites need not have privacy poli
 cies, however, and if they do, the content goes unregu
 lated. The United States' trading partners are justifiably
 concerned by this neglect for consumer privacy, and
 the Federal Trade Commission's recent backtracking
 on guarantees for online privacy for children will
 increase discomfort25
 Although US regulators have been derelict in pro
 tecting the general privacy of citizens, concerns
 regarding the privacy of health information in the
 United States are not necessarily warranted. The new
 federal standards for privacy of individually identifiable
 health information26 (and related draft security regula
 tions) issued under the Health Information Portability
 and Accountability Act (HIPAA) provide the world's
 most robust protection for medical information,
 although recent developments in Australia threaten
 that status.27
 Most modern privacy regimes, including the EU
 data protection directive,28 are collection-centric. That
 is, they limit the collection of consumer information,
 frequently by reference to a concept such as
 proportionality. Serious questions arise, however, as to
 whether health privacy regimes should place any limits
 on the collection of patient data, at least for purposes
 related to treatment Thus HIPPA is a disclosure
 centric confidentiality scheme. It protects patient infor
 mation by prohibiting most disclosures unless they are
 preceded by highly regulated processes of consent for
 treatment or payment purposes. Even more stringent
 provisions, together with a "minimum necessary" rule,
 limit disclosures for other purposes, such as marketing
 or fundraising.
 These privacy and security rules were not
 developed in a vacuum. US regulators are introducing
 a vasdy more efficient system for health transactions,
 based on electronic data interchange. Unfortunately,
 this origin exposes the fundamental flaw in the HIPAA
 privacy and security schemes: they apply only to
 healthcare entities that use the electronic data
 interchange system. As a result, hospitals, doctors, and
 health insurers are likely to find their internet activities
 regulated, while the more typical ecommerce sites
 offering health advice or medical products, which col
 lect and resell customer information, are far less likely
 to fall within the regulatory scope. State statutory and
 common law systems that provide higher levels of pri
 vacy protection are not, however, pre-empted by the
 federal HIPAA scheme. These unharmonised state law
 protections will become increasingly important as
 health websites sell their visitor data to research
 companies29 and if healthcare organisations continue
 their unfortunate accidental postings of confidential
 patient information on the web.30
 Conclusion
 Industry consolidation around a few well known
 brands and the dotcom implosion have taken their
 toll on health advice sites. In the near term the major
 ehealth players will be drawn from basic health
 organisations looking to technology to improve the
 quality and efficiency of their services31 and govern
 ment agencies seeking to improve healthcare delivery
 to underserved populations.
 It is both appropriate and practical to shift regula
 tory emphasis away from advice sites. Outdated,
 inaccurate, fraudulent, or even dangerous information
 on the web is notoriously difficult to regulate. Our
 regulatory energies are better devoted to pressing
 health information problems that are soluble, such as
 Balkanised approaches to regulating cross border
 health interactions and the security and privacy of per
 sonal medical information.
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